Up-to-date pharmacological standard for primary and secondary prevention of cardiovascular diseases is called with acronym 2ABS and includes treatment with (A) antiplatelet agents (acetylsalicylic acid, thienopyridines), (A) angiotensin-converting enzyme inhibitors, (B) beta-blockers and (S) statins. However new pharmacological options for cardiovascular patients are being currently tested. Also modern invasive treatment is associated with aggressive pharmacological treatment with several drugs. New aspects and trends in management of hart failure, coronary artery disease and acute coronary syndromes will be discussed in presentation.

• Legal notice:
  

  Copyright (c) Pielaszek Research, all rights reserved.
  The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
  In every case, proper references including Author(s) name(s) and URL of this webpage: https://science24.com/paper/7339 must be provided.